Brief: Genmab Announces Q1 Nets Sales Of Darzalex
April 15 (Reuters) - Genmab A/S GMAB.CO: ANNOUNCES NET SALES OF DARZALEX (DARATUMUMAB) FOR FIRST QUARTER OF 2025 NET TRADE SALES OF DARZALEX SOLD UNDER TRADENAME DARZALEX FASPRO IN U.S.), AS REPORTED BY J&J WERE USD 3,237 MILLION IN Q1 OF 2025 NET TRADE SALES WERE USD 1,829 MILLION IN U.S. AND USD 1,409 MILLION IN REST OF WORLD Source text: ID:nGNE97RSw0 Further company coverage: GMAB.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss